** Shares of Marksans Pharma MARK.NS jump 15.6% to 254.7 rupees, their highest since July 2025
** Co's Q4 consol net profit rises 63.6% to 1.48 billion rupees ($15.5 million), rev from ops rises 20.8% to 8.56 billion rupees
** Co says rev growth led by strong recovery in co's UK revenue due to multiple product launches and improved order flow
** Adds price erosion in its UK products stabilised during the quarter
** Trading vols at 13x the 30-day average
** YTD, stock up ~38%
($1 = 95.4475 Indian rupees)
(Reporting by Mridula Kumar in Bengaluru)
((Mridula.Kumar@thomsonreuters.com;))